Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF Models: Study
AstraZeneca’s experimental oral therapy saracatinib — originally developed to treat certain cancers — was found to be at least as effective, and even superior to the approved therapies Ofev (nintedanib) and Esbriet (pirfenidone) in treating idiopathic pulmonary fibrosis (IPF) in several preclinical models of the respiratory disease. Saracatinib worked…